Intra-Cellular Therapies
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Intra-Cellular Therapies generated cash of -$124,199,000, which is more than the previous year. Cash used in financing activities reached the amount of $17,810,000 last year. Net change in cash is therefore -$848,000.
Cash Flow
| 2014 | -22.80M | -66.73M | 115.71M |
|---|---|---|---|
| 2015 | -102.27M | -361.77M | 449.89M |
| 2016 | -91.25M | 92.26M | 477.73K |
| 2017 | -80.49M | -92.71M | 162.35M |
| 2018 | -118.16M | 134.64M | 685.18K |
| 2019 | -127.98M | 177.43M | 3.23M |
| 2020 | -230.07M | -480.29M | 664.17M |
| 2021 | -259.54M | 280.34M | 11.51M |
| 2022 | -270.18M | -128.37M | 455.15M |
| 2023 | -124.19M | 105.54M | 17.81M |
ITCI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 150.36M | 93.76M | 61.44M | 107.63M | 54.94M | 37.79M | 48.64M | 47.15M | 61.32M | 35.15M |
Operating activities | ||||||||||
Net income | -139.67M | -256.25M | -284.12M | -227.00M | -147.72M | -155.12M | -97.77M | -116.42M | -104.79M | -30.69M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 528K | 656K | 533.36K | 528.11K | 477.12K | 368.67K | 213.87K | 196.87K | 139.62K | 25.48K |
Stock-based compensation expense | 52.83M | 43.01M | 34.30M | 24.11M | 20.78M | 17.39M | 14.64M | 14.70M | 10.89M | 3.84M |
| Deferred income tax benefit | 52.83M | 43.01M | 34.30M | 24.11M | 20.78M | 17.39M | 14.64M | 14.70M | 10.89M | 3.84M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -38.82M | -55.03M | -9.39M | -10.76M | 0 | 0 | 94.33K | -63.67K | 20.94K | 284.71K |
Inventories | -26.34M | -15.97M | -891.74K | -7.05M | 0 | 0 | 331.90K | 6.16M | -10.61M | 0 |
Accounts payable | 1.05M | 1.70M | 3.18M | -1.92M | -6.53M | 7.78M | 2.41M | 2.12M | -419.86K | -1.34M |
Cash generated by operating activities | -124.19M | -270.18M | -259.54M | -230.07M | -127.98M | -118.16M | -80.49M | -91.25M | -102.27M | -22.80M |
Investing activities | ||||||||||
Purchases Of Investments | -415.26M | -759.20M | -224.57M | -755.62M | -80.72M | -271.15M | -520.92M | -395.75M | -514.30M | -103.60M |
Investments In Property Plant And Equipment | -269K | -778K | -325.73K | -266.72K | -700.39K | -391.26K | -723.42K | -48.96K | -860.59K | -11.76K |
Acquisitions Net | 0 | 127.59M | -280.66M | 480.02M | -178.13M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 105.54M | -128.37M | 280.34M | -480.29M | 177.43M | 134.64M | -92.71M | 92.26M | -361.77M | -66.73M |
Financing activities | ||||||||||
Common Stock Issued | 17.81M | 433.71M | 11.51M | 652.71M | 3.23M | 685.18K | 162.07M | 233.77M | 449.99M | 116.19M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -125M | 0 | 0 |
Cash used in financing activities | 17.81M | 455.15M | 11.51M | 664.17M | 3.23M | 685.18K | 162.35M | 477.73K | 449.89M | 115.71M |
Net Change In Cash | -848K | 56.6M | 32.31M | -46.19M | 52.68M | 17.15M | -10.85M | 1.48M | -14.16M | 26.17M |
Cash at end of period | 149.51M | 150.36M | 93.76M | 61.44M | 107.63M | 54.94M | 37.79M | 48.64M | 47.15M | 61.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |